The United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and potentially highly potent small ...
- The first patient has been dosed in the ONKORAS-101 trial for the study of BBO-8520 in adult subjects with KRAS G12C non-small cell lung cancer - BBO-8520 is a first-in-class orally bioavailable and ...
PALO ALTO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results